Trials / Completed
CompletedNCT00406887
Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis
Phase 3 Confirmatory Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treatment of Anterior Uveitis (Including Panuveitis).
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 140 (planned)
- Sponsor
- Sirion Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this phase 3 confirmatory study is to determine if difluprednate ophthalmic emulsion is effective in the treatment of treatment of uveitis.
Detailed description
The objective of this phase 3 study is to assess the efficacy and safety of 0.05% difluprednate ophthalmic emulsion (DFBA) in patients with endogenous anterior uveitis, in comparison with 0.1% betamethasone sodium phosphate ophthalmic solution (BP).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Difluprednate Ophthalmic Emulsion |
Timeline
- Start date
- 2002-08-01
- Completion
- 2003-11-01
- First posted
- 2006-12-04
- Last updated
- 2006-12-04
Source: ClinicalTrials.gov record NCT00406887. Inclusion in this directory is not an endorsement.